登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，3月2日，COVID-19 and the anti-lessons of history》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-04

  • COVID-19 and the anti-lessons of history

    Robert Peckham

    Published:March 02, 2020DOI:https://doi.org/10.1016/S0140-6736(20)30468-2

    As the outbreak of coronavirus disease 2019 (COVID-19) in China's Hubei province continues and new cases of the disease increase globally, there is pressure on historians to show the value of history for policy. How can the past assist in the real-time management of the crisis? What insights can be gleaned from the ongoing epidemic for future disease preparedness and prevention? Lurking in the background of these interrogatives is a more or less explicit accusation: why haven't past lessons been learned? The gist of some commentaries seems to be: “there is almost nothing surprising about this pandemic”.

  • 原文来源：https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30468-2/fulltext
12浏览量
原文链接
相关报告

  • 《3月2日_COVID-19和历史的反思》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-04
    • 1.时间：2020年3月2日 2.机构或团队：香港大学 3.事件概要： 香港大学的Robert Peckham在《the Lancet》上发表评论文章“COVID-19 and the anti-lessons of history”，对历史事件与COVID-19带来的经验教训进行了探讨。 文章提到，随着中国湖北省2019年冠状病毒疾病暴发（COVID-19）的持续爆发以及全球范围内新发病例的增加，历史学家迫切需要展示政策历史的价值，过去如何帮助实时管理危机，从持续的流行病中可以收集到哪些经验，以用于未来的疾病预防和预防，根据对武汉市首批425例确诊病例的分析，对该疾病的传染性进行了早期估计，并与1918-19年流感大流行进行了比较。 文章提到，很少将COVID-19的类比扩展到涵盖这些相互交织的社会和政治环境。尽管历史上的权宜之计被低估了，但这些经验教训使人们对这段历史有所了解。历史学家需要对错误的类比提出质疑，这些类比掩盖了而不是阐明了部分导致新感染的社会过程。他们需要在总结性课程中挑战过去的束缚，这种方法可以帮助确保在各种边界在全球范围内崛起之时，对突发事件采取战略开放态度。 4.附件： 原文链接： https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30468-2/fulltext
    174浏览量
    原文链接

  • 《LANCET，2月27日，COVID-19: combining antiviral and anti-inflammatory treatments》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-28
    • COVID-19: combining antiviral and anti-inflammatory treatments Justin Stebbing, Anne Phelan, Ivan Griffin, Catherine Tucker, Olly Oechsle, Dan Smith, et al. Published:February 27, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30132-8 Both coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) are characterised by an overexuberant inflammatory response and, for SARS, viral load is not correlated with the worsening of symptoms.1, 2 In our previous Correspondence to The Lancet,3 we described how BenevolentAI's proprietary artificial intelligence (AI)-derived knowledge graph,4 queried by a suite of algorithms, enabled identification of a target and a potential therapeutic against SARS coronavirus 2 (SARS-CoV-2; the causative organism in COVID-19). We identified a group of approved drugs that could inhibit clathrin-mediated endocytosis and thereby inhibit viral infection of cells (appendix). The drug targets are members of the numb-associated kinase (NAK) family—including AAK1 and GAK—the inhibition of which has been shown to reduce viral infection in vitro.5, 6 Baricitinib was identified as a NAK inhibitor, with a particularly high affinity for AAK1, a pivotal regulator of clathrin-mediated endocytosis. We suggested that this drug could be of use in countering SARS-CoV-2 infections, subject to appropriate clinical testing.
    120浏览量
    原文链接